









Markets
/
Stocks
/
nasdaq-teva
/

Teva Pharmaceutical Industries Ltd

TEVA



View Detailed Chart

29.790USD

-0.380-1.26%

Close 12/12, 16:00（ET）Quotes delayed by 15 min

34.18BMarket Cap

47.88P/E TTM



Teva Pharmaceutical Industries Ltd

29.790

-0.380-1.26%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.26%

5 Days

+4.67%

1 Month

+16.64%

6 Months

+75.34%

Year to Date

+35.16%

1 Year

+80.55%

View Detailed Chart

TradingKey Stock Score of Teva Pharmaceutical Industries Ltd

Currency: USD Updated: 2025-12-12

Key Insights

Teva Pharmaceutical Industries Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 38/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.64.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Teva Pharmaceutical Industries Ltd's Score

Industry at a Glance

Industry Ranking

38 / 159

Overall Ranking

109 / 4592

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

28.638

Target Price

+1.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Teva Pharmaceutical Industries Ltd Highlights

StrengthsRisks

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Overvalued

The company’s latest PE is 47.88, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 742.23M shares, decreasing 10.27% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 114.00 shares of this stock.